Biota Pharmaceuticals to Present at Rodman & Renshaw 17th Annual Global Investment Conference


ATLANTA, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota's CEO & President Joseph Patti, PhD will present a corporate overview at the Rodman & Renshaw 17th Annual Global Investment Conference on Wednesday, September 9, 2015 at 4:15 p.m. ET in New York, NY.

A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors section of the Company's website at www.biotapharma.com or at http://wsw.com/webcast/rrshq25/bota. A replay of the webcast will be archived for 30 days following the presentation.

About Biota Pharmaceuticals, Inc.

Biota Pharmaceuticals is focused on the discovery and development of direct-acting antivirals to treat infections that affect a significant number of patients globally. The Company has four product candidates in clinical development that address viral infections that have limited therapeutic options. Vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics, is currently being evaluated in the Company's ongoing Phase 2b SPIRITUS trial; BTA074, a Phase 2 topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion (F) protein inhibitor in Phase 1 development for the treatment of RSV-A and RSV-B infections; laninamivir octanoate, a one-time, inhaled treatment in Phase 2 development for influenza A and B infections; and a preclinical stage RSV non-fusion inhibitor program that complements our F-protein inhibitor BTA585.For additional information about the Company, please visit www.biotapharma.com.

Biota is a registered trademark of Biota Pharmaceuticals, Inc.


            

Contact Data